Natco launches Rs 1,290 semaglutide in India, undercuts diabetes drug prices

Natco Pharma has launched a new generic semaglutide injection in India. This marks a significant step in making advanced diabetes treatment more accessible. The drug is available at a much lower price compared to existing options. This move is expected to benefit a large number of diabetic patients across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/InWTzCi
via IFTTT